Niosomes as transdermal drug delivery system for celecoxib: in vitro and in vivo studies

被引:40
作者
Auda, Sayed H. [1 ,2 ]
Fathalla, Dina [3 ]
Fetih, Gihan [3 ]
El-Badry, Mahmoud [1 ,3 ]
Shakeel, Faiyaz [1 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmaceut, POB 2457, Riyadh 11451, Saudi Arabia
[2] Al Azhar Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Assiut, Egypt
[3] Assiut Univ, Fac Pharm, Dept Pharmaceut, Assiut 71526, Egypt
关键词
Celecoxib; Niosomal gel; Kinetic study; Skin permeation; Anti-inflammatory activity; PERCUTANEOUS-ABSORPTION; ANTIINFLAMMATORY ACTIVITY; TOPICAL APPLICATION; GEL; FORMULATION; SKIN; PENETRATION; NANOEMULSION; PERMEATION; CARRIERS;
D O I
10.1007/s00289-015-1544-8
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Nonionic surfactant vesicles containing celecoxib (CXB) as an anti-inflammatory drug were prepared using, Span 60 or Span 40 and cholesterol in the ratios of 1:0, 1:1 and 1:2. Prepared vesicles were characterized for encapsulation efficiency, particle size and drug release. The drug encapsulation efficiencies varied from 60.55 to 80.35 %. The vesicle size ranged from 170 to 235 nm. The high encapsulation was achieved by the ratio 1:1 of span 60:cholesterol and this formula showed significant in vitro release of the drug (80 %) as compared to other forms (P < 0.05). Among niosomal gels investigated, poloxamer 407 niosomal gel showed significant drug release (72 % after 12 h) over the other forms (P < 0.05). The results also showed that the release of CXB from the niosomes and niosomal gels obeyed the Higuchi's diffusion model. The anti-inflammatory activity of the drug from different niosomal gel formulations was also studied using Carrageenan-induced rat paw edema method. The results showed that there is significant anti-inflammatory activity (75.45 %) of the poloxamer niosomal gel on rat paw edema (P < 0.05).
引用
收藏
页码:1229 / 1245
页数:17
相关论文
共 55 条
[41]  
Shahiwala A, 2002, J PHARM PHARM SCI, V5, P220
[42]   Celecoxib Nanoemulsion for Transdermal Drug Delivery: Characterization and In Vitro Evaluation [J].
Shakeel, F. ;
Baboota, S. ;
Ahuja, A. ;
Ali, J. ;
Shafiq, S. .
JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY, 2009, 30 (06) :834-842
[43]   Chemoprevention of skin cancer using low HLB surfactant nanoemulsion of 5-fluorouracil: a preliminary study [J].
Shakeel, Faiyaz ;
Haq, Nazrul ;
Al-Dhfyan, Abdullah ;
Alanazi, Fars K. ;
Alsarra, Ibrahim A. .
DRUG DELIVERY, 2015, 22 (04) :573-580
[44]   Nanoemulsions as potential vehicles for transdermal and dermal delivery of hydrophobic compounds: an overview [J].
Shakeel, Faiyaz ;
Shafiq, Sheikh ;
Haq, Nazrul ;
Alanazi, Fars K. ;
Alsarra, Ibrahim A. .
EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (08) :953-974
[45]  
Shakeel F, 2008, J DRUG TARGET, V16, P733, DOI [10.1080/10611860802473402, 10.1080/10611860802473402 ]
[46]   Tulsi oil as a potential penetration enhancer for celecoxib transdermal gel formulations [J].
Shamsher, Areeg A. ;
Charoo, Naseem A. ;
Rahman, Ziyaur ;
Pillai, Krishna K. ;
Kohli, Kanchan .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2014, 19 (01) :21-30
[47]  
Soliman SM, 2010, DRUG DISCOV THER, V4, P459
[48]   Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention [J].
Solomon, SD ;
McMurray, JJV ;
Pfeffer, MA ;
Wittes, J ;
Fowler, R ;
Finn, P ;
Anderson, WF ;
Zauber, A ;
Hawk, E ;
Bertagnolli, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1071-1080
[49]   Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion [J].
Subramanian, N ;
Ghosal, SK ;
Moulik, SP .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (4-5) :405-416
[50]  
Tindall Elizabeth, 1999, J Am Osteopath Assoc, V99, pS13, DOI 10.7556/jaoa.1999.99.11.S13